Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Open Access
- 15 October 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (8), 2526-2534
- https://doi.org/10.1182/blood.v98.8.2526
Abstract
Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. This study demonstrates that the trifunctional bsAb BiLu is able to kill tumor cells very efficiently without any additional costimulation of effector cells in vitro and in vivo. Remarkably, this bsAb also induces a long-lasting protective immunity against the targeted syngeneic mouse tumors (B16 melanoma and A20 B-cell lymphoma, respectively). A strong correlation was observed between the induction of a humoral immune response with tumor-reactive antibodies and the survival of mice. This humoral response was at least in part tumor specific as shown in the A20 model by the detection of induced anti-idiotype antibodies. Both the survival of mice and antitumor titers were significantly diminished when F(ab′)2 fragments of the same bsAb were applied, demonstrating the importance of the Fc region in this process. With the use of T-cell depletion, a contribution of a cellular antitumor response could be demonstrated. These results reveal the necessity of the Fc region of the bsAb with its potent immunoglobulin subclass combination mouse immunoglobulin G2a (IgG2a) and rat IgG2b. The antigen-presenting system seems to be crucial for achieving an efficient tumor cell killing and induction of long-lasting antitumor immunity. Hereby, the recruitment and activation of accessory cells by the intact bsAb is essential.Keywords
This publication has 28 references indexed in Scilit:
- The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cellsBritish Journal of Cancer, 2000
- Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Clinical Development of 2B1, a Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and FcγRIIIJournal of Hematotherapy, 1995
- The role of lymphocyte subsets and adhesion molecules in T cell‐dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodiesEuropean Journal of Immunology, 1995
- Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T CellsScience, 1994
- Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule.The Journal of cell biology, 1994
- SINGLE AS WELL AS PAIRS OF SYNERGISTIC ANTI-CD4+CD8 ANTIBODIES PREVENT GRAFT-VERSUS-HOST DISEASE IN FULLY MISMATCHED MICETransplantation, 1994
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proceedings of the National Academy of Sciences, 1993
- Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3European Journal of Immunology, 1991
- Production and characterization of a rat monoclonal antibody against the murine CD3 molecular complexImmunology Letters, 1989